Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Spherix Incorporated (SPEX)

1.14   -0.03 (-2.56%) 01-24 16:00
Open: 1.16 Pre. Close: 1.17
High: 1.2076 Low: 1.14
Volume: 1,673 Market Cap: 6M
Spherix Inc is a patent commercialization company whose operations are focused on the monetization of its intellectual property.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.211 - 1.219 1.219 - 1.225
Low: 1.125 - 1.133 1.133 - 1.139
Close: 1.129 - 1.141 1.141 - 1.151

Technical analysis

as of: 2020-01-24 4:35:45 PM
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 1.56     One year: 1.73
Support: Support1: 1.10    Support2: 0.92
Resistance: Resistance1: 1.33    Resistance2: 1.48
Pivot: 1.23
Moving Average: MA(5): 1.16     MA(20): 1.26
MA(100): 1.46     MA(250): 2.42
MACD: MACD(12,26): -0.02     Signal(9): -0.01
Stochastic oscillator: %K(14,3): 19.88     %D(3): 19.96
RSI: RSI(14): 41.51
52-week: High: 4.26  Low: 1.03  Change(%): -65.7
Average Vol(K): 3-Month: 4462  10-Days: 2448

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
SPEX has closed above bottom band by 17.3%. Bollinger Bands are 24.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Spherix Launches Newly Redesigned Website
NEW YORK, Jan. 21, 2020 /PRNewswire/ -- Spherix Incorporated (Nasdaq: SPEX) today announced that it has redesigned the company's website ( to illuminate the overall digital transformation and recently acquired anti-cancer therapeutics. The new digital platform will…

Promising Early Launch Metrics for AbbVie's Rinvoq (upadacitinib) to Help JAK Inhibitors Solidify Their Position as Second-Line Leaders in Rheumatoid Arthritis, According to Spherix Global Insights
EXTON, Pa. , Dec. 16, 2019 /PRNewswire/ -- Spherix examined the charts of 1,021 rheumatoid arthritis (RA) patients recently switched from one biologic/JAK to another agent via the 2019 annual RealWorld Dynamix™: Biologic/JAK Switching in Rheumatoid Arthritis (US) service. The patient chart analysis revealed that TNF inhibitor cycling remains the most common switch pattern among RA patients, though has leveled off over the past year after steady decreases since 2016. Nevertheless, the percent of patients being switched from one TNF inhibitor to another drops with each line of biologic/JAK therapy, as rheumatologists are more inclined to prescribe an alternate mechanism agent in the second- or later-line setting. While the percent of patients being switched to a TNF inhibitor stands unchanged from the prior year, switches to JAK inhibitors have increased in popularity – likely at the expense of the IL-6 inhibitor class, which had been experiencing year over year gains in the switch- to segment up until the current year (reverting back to figures reported in 2016).

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ Capital Market
Sector:  Industrials
Industry:  Business Services
Shares Out. (M) 4.83
Shares Float (M) 0.92
% Held by Insiders 68.18
% Held by Institutions 2.83
Shares Short (K) 3
Shares Short P. Month (K)

Stock Financials

EPS 0.145
Book Value (p.s.) 3.310
PEG Ratio
Profit Margin 1235.71
Operating Margin -11553.57
Return on Assets (ttm) -23.4
Return on Equity (ttm) 4.6
Qtrly Rev. Growth
Gross Profit (p.s.) -0.204
Sales Per Share
EBITDA (p.s.) -0.366
Qtrly Earnings Growth
Operating Cash Flow (M) -2.67
Levered Free Cash Flow (M) -1.69

Stock Valuations

P/E 7.86
P/E Growth Ratio -0.03
P/BV 0.34
P/S 113.99
P/CF -2.06

Dividends & Splits

Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date 1980-05-11
Forward Dividend
Last Split Date 2019-05-09
Last Split Ratio -1e+010
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2019 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.